Clinical Trial Update: Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of anti-CTLA4-NF mAb (BMS-986218), nivolumab, and stereotactic body radiation therapy for metastatic solid malignan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma
• Hepatocellular Carcinoma
• Lung Cancer

Drugs mentioned

• BMS-986218 (non-fucosylated anti-CTLA-4 antibody)
• OPDIVO (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: TERMINATED